MedTrace Logo

Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

NCT01736943 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-02-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether bortezomib in combination with doxil/lipodox is effective in the treatment of Acute Myeloid Leukemia.

Conditions

  • Acute Myelogenous Leukemia

Interventions

DRUG

Bortezomib

Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.

DRUG

Doxil

Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.

Sponsors & Collaborators

  • Millennium Pharmaceuticals, Inc.

    collaborator INDUSTRY

  • Joseph Tuscano

    lead OTHER

Principal Investigators

  • Joseph Tuscano, MD · University of California, Davis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-19
Primary Completion
2019-05-20
Completion
2019-05-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01736943 on ClinicalTrials.gov